Algorae Pharmaceuticals (ASX:1AI) successfully launches AlgoraeOS Artificial Intelligence Platform

24 September 2024

Price Sensitive Announcement $

Highlights:

• Successful launch of AlgoraeOS pla2orm, with Technology Readiness Level (“TRL”) 3+
• AI models validated for fixed-dose combination (“FDC”) drug target prediction
• High prediction correlation in major synergy metrics ranging from 0.91 – 0.98 “predicted” versus “actual”
• Next major milestone: combination drug candidate prediction, laboratory validation and
  implementation of intellectual property strategies.

Overview:

Algorae Pharmaceuticals Limited has announced the successful launch of its proprietary artificial intelligence platform, AlgoraeOS.

The platform, launched on schedule, has achieved a Technology Readiness Level (“TRL”) of 3+, an internationally recognized metric for evaluating technological progress. AlgoraeOS integrates four proprietary AI neural networks to analyse vast datasets, predicting fixed-dose combination (“FDC”) drug targets. It operates on the ‘Gadi’ supercomputer, managed by National Computational Infrastructure (“NCI Australia”), which has previously been utilised for projects like climate modelling and natural disaster prediction.

To drive this platform to enterprise standards, Algorae is collaborating with leading experts from the UNSW AI Institute, with economic support from the data and digital specialist arm of Australia’s national science agency, CSIRO Data61. AlgoraeOS is wholly owned by Agorae and will undergo iterative improvements over the next 2.5 years, with version 2.0 development already underway. Pleasingly, initial system training indicated high prediction correlation of major synergy metrics (Bliss, Loewe and HSA) ranging from 0.91 – 0.98 “predicted” versus “actual” data, facilitating high confidence in the model.

Initial in-silico FDC drug target predictions from AlgoraeOS are expected to be reported for company analysis in the coming weeks. Planning of pre-clinical assessments are under discussion with laboratory partners, focusing on development paths, intellectual property strategies, and potential commercial partnerships. Further updates on these collaborations will follow.

Company Notes:

Chairman David Hainsworth added: “The launch of AlgoraeOS marks a significant step in our strategy to leverage AI for developing fixed-dose combination drugs. By improving existing therapies rather than investing in new molecular entities, we can enhance drug efficacy while compressing the timelines and costs. This intersection of AI and drug development represents a major commercial opportunity for our shareholders and benefits the broader community through access to improved treatments.”

Full ASX Announcement: https://app.sharelinktechnologies.com/announcement/asx/fb615859694fae66b06dbb6ab1f2aa08